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Abstract: Chemotherapy, irradiation, and other agents are widely used to target the process 
of cell division in neoplastic cells. However, while these therapies are effective against most 
cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions 
of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in 
loss of blood cell populations, which can be life threatening. Neutropenia is the most serious 
hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality 
due to opportunistic infection and often is the limiting factor in dose escalation or duration of 
chemotherapeutic administration. Neutropenic patients often require hospitalization and incur 
substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and 
congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupo-
gen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, 
biosimilars have begun to emerge. In this review, we will summarize the chemical characteris-
tics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting 
biosimilar filgrastim to receive regulatory approval and enter the marketplace.
Keywords: granulocyte-colony stimulating factor, biosimilar, filgrastim, neutrophil, XM22, 
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Introduction
The use of chemotherapeutics to treat malignancies is rooted in the use of mustard gas 
during the World Wars. Sinking of the USS John Harvey carrying a cargo of mustard 
bombs in the port city of Bari, Italy, in 1943 released the toxic payload and exposed 
survivors and residents to nitrogen mustard gas. Within 3–4 days, many of those 
exposed had severe drops in their white blood cell counts.1 Hypothesizing that the 
actions of the mustard gas on white blood cells could potentially be used to treat hemato-
logic diseases, several clinicians studied the effectiveness of intravenously administered 
nitrogen mustards, tris(β-chloroethyl)amine and methyl-bis(β-chloroethyl)amine, and 
published landmark findings in 1946 that nitrogen mustards were effective in treating 
various forms of leukemia and lymphoma.2 Their conclusion heralded in the era of 
cancer chemotherapeutic discovery:
Chemicals discovered to be therapeutically active in neoplastic disease deserve 
close study [...]. From this point of view the heuristic aspects of the actions of the 
β-chloroethylamines here reported may eventually prove of greater importance than 
the chemical results obtained to date.2
Cancer is traditionally thought of as unregulated cell replication, where tumor 
cells acquire mutations allowing them to bypass normal cell cycle checkpoints and 
apoptosis regulatory pathways. Nitrogen mustards work by alkylating DNA, preventing 
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cell division, and causing cell cycle checkpoint-mediated 
apoptosis. Many chemotherapeutic agents similarly target 
cell division. Unfortunately, this mechanism of action is 
not specific to malignant cells, resulting in chemotherapy-
related toxicities to healthy tissue. The nonspecific effects 
of most chemotherapeutic agents are the primary limiting 
factor in the treatment of malignancies. Methods to reduce 
these toxicities therefore allow for higher dosage regimens 
of chemotherapeutics and enhance clinical outcomes in many 
forms of cancer.
The blood-producing hematopoietic system is particularly 
susceptible to the toxicities of chemotherapeutics given the 
production demand of approximately 1 trillion blood cells 
daily.3 The most abundant white blood cells in the blood 
are neutrophils, which are essential members of the innate 
immune system and provide protection from a wide variety 
of bacterial and fungal pathogens. Given the abundance of 
neutrophils and their short half-life in the blood of 6–8 hours, 
the production rate from hematopoietic progenitor cells in 
the bone marrow is 5×1010 to 10×1010 neutrophils per day.4 
The notable amount of cell divisions required to meet this 
high cellular demand makes the myeloid compartment of the 
bone marrow hematopoietic system particularly susceptible 
to chemotherapy.
Chemotherapy-induced neutropenia
Neutropenia is the most serious hematologic toxicity of 
chemotherapy and often is the limiting factor in dose esca-
lation or duration of chemotherapeutic administration.5 
The National Cancer Institute’s Common Toxicity Criteria 
rates the severity of neutropenia into five classifications: 
Grade 1 is 2.0×109–1.5×109 cells/L; Grade 2 is 1.5×109–
1.0×109 cells/L; Grade 3 1.0×109–0.5×109 cells/L; Grade 4 
is 0.5×109 cells/L; and Grade 5 is death.6 Neutrophils are 
the primary cellular mediators of the innate immune system 
and the first line of defense to numerous pathogens. Neutro-
penic patients are susceptible to infections from the respira-
tory tract (35%–40% of cases), bloodstream (15%–35%), 
urinary tract (5%–15%), skin (5%–10%), gastrointestinal 
tract (5%–10%), and other sites (5%–10%).7 Many of the 
symptoms manifested in response to bacterial infection 
are a consequence of the inflammatory immune response 
to the pathogen. In neutropenic patients, because they lack 
neutrophils that are mounting the normal response, they lack 
many of the normal symptoms of infection and hence it can 
go unnoticed. Oftentimes, the only clinical sign of infection 
early on is a fever, which defines a serious clinical outcome 
of chemotherapy known as “febrile neutropenia”, having 
Grade 4 neutropenia with a fever greater than 38.3°C. More 
than 60,000 patients are hospitalized annually as a result of 
neutropenia, and these hospitalizations are estimated to have 
resulted in $13,400 in medical costs.8 The average costs for 
febrile neutropenia encounters were reported to be $22,086, 
with patients who had febrile neutropenia incurring a mean 
cost difference of $1,149 per patient, per month.9 Similarly, 
another study reported that mean hospitalization costs per 
patient were $18,042 for patients with neutropenia, $22,839 
for patients with neutropenia plus infection or fever, and 
$27,587 for patients with neutropenia plus infection.10 There-
fore, boosting the bone marrow production of neutrophils is 
imperative to successful chemotherapy treatment and reduc-
tion of medical costs.
The landscape of febrile neutropenia was changed dra-
matically in the mid-1980s with the molecular cloning of 
granulocyte colony–stimulating factor (G-CSF).11–14 Initially 
believed to be a multipotent hematopoietic growth factor as 
well an inducer of granulocyte differentiation, G-CSF was 
found to stimulate proliferation15,16 and differentiation13 of 
several types of myeloid progenitor cells alone and in com-
bination with other growth factors,17–19 and this stimulation 
of progenitor cells leads to a significant increase in mature 
neutrophil output. The first clinical trials were performed 
in cancer patients receiving chemotherapy20–23 leading to 
US Food and Drug Administration approval in 1991 of 
Neupogen® (filgrastim). Filgrastim is approved to decrease 
the incidence of neutropenia in patients with nonmyeloid 
malignancies receiving chemotherapeutics associated with 
a significant incidence of severe neutropenia with fever; to 
reduce incidence and duration of neutropenia in patients with 
congenital, cyclic, or idiopathic neutropenia; for reducing the 
time to neutrophil recovery and the duration of fever, fol-
lowing induction or consolidation chemotherapy treatment 
of adults with acute myeloid leukemia (AML); and to reduce 
the duration of neutropenia and neutropenia-related clinical 
sequelae, eg, febrile neutropenia, in patients with nonmyeloid 
malignancies undergoing myeloablative chemotherapy fol-
lowed by hematopoietic transplantation.
While successful, the burden and associated pain of daily 
injections of filgrastim can result in patient discomfort and/
or noncompliance, resulting in missed doses and reduced 
efficacy. Improved dosage forms that reduce the daily injec-
tion requirement can thus lead to enhanced patient care. 
A longer lasting monomethoxy polyethylene glycol (PEG)–
conjugated filgrastim (pegfilgrastim; Neulasta®) having the 
same mechanism of action24 and clinical effects compared to 
filgrastim25 was subsequently introduced, but requires only 
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single administration per cycle of chemotherapy rather than 
multiple daily injections of filgrastim.26 Since the introduction 
of filgrastim and pegfilgrastim to clinical practice, the man-
agement of neutropenia has been enhanced, and several 
biosimilars have recently entered the marketplace and oth-
ers are in development (reviewed in Hoggatt and Pelus27). 
To date, only a single long-acting biosimilar filgrastim has 
been introduced. This review will focus on lipegfilgrastim 
(Lonquex®) approved by the European Medicines Agency 
(EMA) for the treatment of neutropenia.
Lipegfilgrastim
Lipegfilgrastim is a long-acting, site-specific glycol-pegylated 
r-metHu G-CSF produced by conjugation of a single 20-kDa 
PEG to the natural O-glycosylation site of G-CSF (threonine 
134), using a novel glycoPEGylation technology (Figure 1). 
Because the recombinant G-CSF is produced in Escheri-
chia coli, the glycosylation site is empty. Addition of the 
O-glycan was achieved by enzymatic activity of a truncated 
N-acetylgalactosaminyltransferase isoform 2 fused with malt-
ose-binding protein at the threonine residue site. A 20-kDa 
PEG-sialic acid derivative was enzymatically transferred 
to the O-glycan with a sialyltransferase. In contrast, peg-
filgrastim (Neulasta®) is a recombinant methionyl human 
G-CSF with a methoxy-polyethylene glycol propionaldehyde 
20-kDa PEG covalently conjugated to its N-terminus.28,29 
The novel pegylation process used in lipegfilgrastim results 
in different pharmacokinetic and pharmacodynamic profiles 
than pegfilgrastim, as discussed later.
In preclinical studies, lipegfilgrastim and pegfilgrastim 
binding to the G-CSF receptor was evaluated using an 
NFS-60 cell-based [125I]-G-CSF competitive G-CSF receptor-
binding assay. In the cell-based [125I]-G-CSF competitive 
G-CSF receptor-binding assay, G-CSF receptor binding 
was equivalent between lipegfilgrastim and pegfilgrastim 
as indicated by the inhibition of [125I]-G-CSF binding 
(0.70±0.09 nM IC
50
 versus 0.72±0.18 nM IC
50
 [mean ± 
standard deviation]).28
Figure 1 Lipegfilgrastim is the result of a two-step enzymatic reaction.
Notes: Addition of an O-glycan at the open threonine 134 site of filgrastim is achieved by enzymatic activity of a selective, truncated N-acetylgalactosaminyltransferase 
isoform 2 fused with maltose-binding protein at the threonine residue within the chosen site. A 20-kDa PEG-sialic acid derivative is then enzymatically transferred to 
the O-glycan with a sialyltransferase.
Abbreviations: G-CSF, granulocyte colony–stimulating factor; PEG, polyethylene glycol.
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Pharmacokinetics
Lipegfilgrastim was evaluated in three separate healthy 
volunteer studies.30,31 In a limited healthy volunteer study, 
three separate subcutaneous injection sites were evaluated; 
upper arm, abdomen, and the thigh. Bioavailability was found 
to be lower after injection in the thigh compared to the upper 
arm or abdomen. However, increases in neutrophil counts 
were similar across the three injection sites and the recom-
mended administration of lipegfilgrastim is for any of these 
three sites.30 In additional clinical studies, lipegfilgrastim was 
administered as a single subcutaneous injection and in some 
analyses compared to pegfilgrastim. In the dose escalation 
phase, administration of lipegfilgrastim was not continued 
beyond 100 µg/kg as two subjects experienced ANC
MAX
 
(maximum absolute neutrophil count) levels greater than 
70 neutrophils/nL, the limit for hyperleukocytosis in healthy 
subjects.31 The maximal blood concentration was reached 
after 30–36 hours postadministration. The terminal half-
life ranged from approximately 32 to 62 hours, which was 
7–10 hours longer for lipegfilgrastim 100 µg/kg compared 
with pegfilgrastim 100 µg/kg.
Lipegfilgrastim is mainly internalized and eliminated by 
neutrophils and can be metabolized via intra- or extracellular 
degradation by proteolytic enzymes, which becomes saturated 
at higher doses. In vitro data suggest there is little to no effects 
on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and 
CYP3A4/5 activity, suggesting lipegfilgrastim does not affect 
human cytochrome P450 metabolism.30
Safety
In conventional safety and pharmacology studies in animal 
models, no special hazard for humans was found. In all 
healthy volunteer studies, the overall safety and tolerability 
was good, and no serious adverse events were reported.31 
While there have been reports of PEGylation-inducing anti-
PEG antibodies in patients,32,33 no subject tested positive for 
antibodies against filgrastim, pegfilgrastim, or lipegfilgrastim 
demonstrating no significant immunogenicity of the com-
pound. In Phase III trials in breast cancer patients, the safety 
of lipegfilgrastim was similar to pegfilgrastim.34,35 The most 
commonly reported adverse events in both treatment groups 
were alopecia, nausea, asthenia, bone pain, diarrhea, fatigue, 
anorexia, vomiting, headache, and myalgia.
Efficacy
Lipegfilgrastim was compared to pegfilgrastim in two 
separate clinical trials. The first trial was a randomized, 
double-blind Phase II study, conducted between June and 
November of 2008.35 This study included screening of 229 
patients and ultimately enrollment of 208 patients at 37 
centers in the Czech Republic, Germany, Hungary, Roma-
nia, Russia, and Ukraine. A total of 202 patients (97.1%) 
completed the study, with three patients withdrawing due 
to adverse events, two withdrew consent, and one was lost 
to follow-up. Male and female patients (only three male 
patients were in the study) 18 years of age with high-
risk stage II, III, or IV breast cancer were eligible if they 
had an Eastern Cooperative Oncology Group performance 
status 2; absolute neutrophil count 1.5×109/L; platelet 
count 100×109/L; and adequate cardiac, hepatic, and renal 
function. Patients had to be chemotherapy-naive and eligible 
for doxorubicin/docetaxel chemotherapy. Patients received 
four 3-week chemotherapy cycles and were randomized 
1:1:1:1 to receive 3.0-, 4.5-, or 6.0-mg lipegfilgrastim or 
6.0-mg pegfilgrastim subcutaneously on chemotherapy day 
2. Chemotherapy consisted of doxorubicin 60 mg/m2 given 
as an intravenous bolus injection followed 1 hour later by a 
1-hour intravenous infusion of docetaxel 75 mg/m2.
No significant difference in the duration of severe neu-
tropenia for the first chemotherapy cycle among the three 
lipegfilgrastim doses and pegfilgrastim was observed. The 
percentage of patients who did not experience severe neutro-
penia was higher in the 6.0-mg lipegfilgrastim dosage group 
(62.0%) compared with the 3.0- and 4.5-mg dosage groups 
(43.4% and 49.0%, respectively). This percentage of patients 
was also higher than the 6.0-mg pegfilgrastim dosage group 
(46.3%). For chemotherapy cycles 2–4, the mean duration of 
severe neutropenia was significantly shorter for the 6.0-mg 
lipegfilgrastim dosage group versus the pegfilgrastim dosage 
group. This study established 6.0-mg lipegfilgrastim as the 
optimal dose for breast cancer patients receiving chemo-
therapy and established noninferiority to pegfilgrastim in 
reducing cycle 1 duration of severe neutropenia.
Following this study, a similar experimental approach was 
taken in a randomized, multicenter Phase III study.34 Breast 
cancer patients receiving chemotherapy were randomized 
1:1 to receive either the 6.0-mg lipegfilgrastim dose (n=101) 
or 6.0-mg pegfilgrastim dose (n=101). Lipegfilgrastim was 
found to be noninferior to pegfilgrastim in the duration of 
severe neutropenia following cycle 1 of chemotherapy, 
with a 95% confidence interval of −0.498%, 0.062% days 
(P=0.1260). Similarly, there was no significant difference in 
the duration of severe neutropenia between the two groups 
following cycles 2–4. Intriguingly, the absolute neutrophil 
count nadir after cycles 2–4 was higher in the lipegfilgrastim 
group compared to the pegfilgrastim group (2.6 vs 2.0, 2.5 
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vs 2.0, and 2.7 vs 2.3×109/L; P=0.0189, P=0.0353, and 
P=0.1122, respectively). Similarly, the time to neutrophil 
recovery was ~1.5 days shorter for the lipegfilgrastim group 
compared to the pegfilgrastim group (P0.05). The results 
of this study further demonstrated noninferiority of 6.0-mg 
lipegfilgrastim compared to 6.0-mg pegfilgrastim and sug-
gest a possible enhancement over pegfilgrastim in neutrophil 
recovery following chemotherapy.
Recently, the results of a double-blind, randomized, 
placebo-controlled study in elderly patients with non–small-
cell lung cancer receiving cisplatin/etoposide chemotherapy 
were reported at the 12th Meeting of the International Society 
of Geriatric Oncology.36 Patients received 6.0-mg lipegfil-
grastim or placebo on day 4 of the chemotherapy cycle, and 
the incidence of febrile neutropenia was assessed. Fewer 
elderly patients receiving lipegfilgrastim (0/53; 0.00%) 
experienced febrile neutropenia compared to the placebo 
group (4/30; 13.33%) (P=0.0064). There was no significant 
difference in incidence severity or type of adverse events 
between the treatment and placebo groups.
Conclusion
Lipegfilgrastim, in the setting of breast cancer chemotherapy–
induced neutropenia is at least as equivalent to pegfilgrastim 
in reducing neutropenic complications. Lipegfilgrastim, 
Lonquex®, represents the first long-acting biosimilar filgrastim 
to reach the market in Germany and has received EMA 
approval and will likely be marketed throughout Europe.
As the Neupogen® and Neulasta® patent lives have ended, 
and given the large economic market of G-CSF therapies in 
reducing the complications associated with chemotherapy, 
there has been a large effort in biosimilar development. 
To date, several filgrastim biosimilars have received US Food 
and Drug Administration and/or EMA approval and have 
entered the marketplace (recently reviewed in Hoggatt and 
Pelus27). While lipegfilgrastim is the first long-acting bio-
similar filgrastim to reach the market, additional long-acting 
biosimilars, some with unique modifications to increase 
half-life, are currently in late-stage clinical development 
(reviewed in Hoggatt and Pelus27). To date, no long-acting 
biosimilar filgrastim has been approved by the US Food 
and Drug Administration. Additionally, dosage forms that 
eliminate the need for injection altogether, such as the topical 
filgrastim product Nupen, may enhance patient compliance 
and resulting care in some clinical applications, although 
further clinical studies are required.
Overall, the use of biosimilar filgrastim and pegfilgrastim 
products will be dictated by market prices and individual 
center preferences until further enhancements in efficacy or 
ease of administration, eg, oral, are identified and developed. 
In the shorter term, it is expected that biosimilar G-CSF 
agonists may reduce the significant medical costs of neutro-
penia treatment and facilitate market expansion.
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